Two-thirds of recent rare disease drugs relied on just one trial, plus confirmatory evidence, FDA team finds
New research published by FDA authors found that 67% of non-oncologic rare disease marketing applications approved between 2020 and 2023 used only one clinical trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
